Cases in Multiple Myeloma: The Role of Oncology Pharmacists on an Interprofessional Team to Improve Patient Care and Outcomes

Target Audience 
The educational design of this activity addresses the needs of pharmacists involved in the treatment of patients with multiple myeloma (MM).

Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with MM.

Educational Objectives
After completing this activity, the participant should be better able to:

• Evaluate emerging data from clinical trials regarding novel agent–based regimens that provide optimal outcomes and a survival benefit for patients with MM eligible and ineligible for SCT.
• Recommend dose adjustments when necessary based on patient- and disease- associated factors.
• Actively participate in adverse event management strategies for patients with MM receiving novel therapies and regimens.

Registered Pharmacy Designation
MLI is accredited by the Accreditation Coun cil for Pharmacy Education (ACPE) as a provider of continuing pharmacy edu cation. Completion of this activity provides for 1 contact hour (0.1 CEU) of continuing education credit. The universal program number for this activity is 0468-9999-11-030-H01-P.

Instructions for Credit
There is no fee for this activity. To receive credit after reading this CE activity in its entirety, participants must complete the posttest and evaluation. The posttest and evaluation can be completed online at www.mlicme.org/P11012E.html. Upon completion of the evaluation and scoring a 70% or better on the posttest, you will immediately receive your certificate online. If you do not achieve a score of 70% or better on the posttest, you will be asked to take it again. Please retain a copy of the Certificate for your records.

For questions regarding the pharmacy accreditation of this activity, please contact MLI at (609) 333-1693 or cgusack@mlicme.org.

Disclosure
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by MLI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Stephanie S. Minich, PharmD, BCOP,  has nothing to disclose.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and Center of Excellence Media, LLC, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CE activity for any amount during the past 12 months. The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Teresa Haile, RPh, MBA, has nothing to disclose.

Disclaimer
The information provided at this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Agenda: 1 hour 
Articles/Commentaries: 45 minutes
Evaluation/Posttest: 15 minutes